Precigen, Inc. (PGEN) News
Filter PGEN News Items
PGEN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PGEN News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest PGEN News From Around the Web
Below are the latest news stories about PRECIGEN INC that investors may wish to consider to help them evaluate PGEN as an investment opportunity.
Precigen to Present at the 43rd Annual J.P. Morgan Healthcare ConferencePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 9:00 AM PT in San Francisco, California. |
Exploring 3 Prominent High Growth Tech Stocks In The United StatesOver the last 7 days, the United States market has dropped 2.6%, yet it remains up by 23% over the past year with earnings anticipated to grow by 15% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies with strong innovation potential and robust financial health that can thrive even amidst short-term market fluctuations. |
Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory PapillomatosisPrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the completion of the rolling submission for a biologics license application (BLA) to the US Food and Drug Administration (FDA) for PRGN-2012 (INN: zopapogene imadenovec†) for the treatment of adult patients with recurrent respiratory papillomatosis (RRP). The submission is in the initial 60 day review period, during wh |
Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred StockPrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that it has entered into a securities purchase agreement for the sale of its 8.00% Series A Convertible Perpetual Preferred Stock (Preferred Stock) in a private placement. Precigen anticipates gross proceeds from the private placement of $79.0 million before deducting offering expenses. In addition, the investors will h |
Precigen (NASDAQ:PGEN shareholders incur further losses as stock declines 13% this week, taking five-year losses to 86%We're definitely into long term investing, but some companies are simply bad investments over any time frame. We don't... |
Precigen Reports Third Quarter 2024 Financial Results and Business UpdatesPrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced third quarter 2024 financial results and business updates. |
Precigen to Participate in the Stifel 2024 Healthcare ConferencePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a fireside chat on Tuesday, November 19, 2024 from 10:55 to 11:25 AM ET at the Stifel 2024 Healthcare Conference taking place November 18 to 19, 2024 in New York. |
High Growth Tech Stocks To Watch In October 2024Over the last 7 days, the United States market has dropped by 1.0%, yet it has seen a substantial rise of 38% over the past year, with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate robust innovation and adaptability to capitalize on these promising earnings projections. |
Precigen to Participate in the 2024 Cantor Global Healthcare ConferencePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a fireside chat on Wednesday, September 18, 2024 from 9:45 to 10:15 AM ET at the 2024 Cantor Global Healthcare Conference taking place September 17 to 19, 2024 in New York. |
While institutions own 26% of Precigen, Inc. (NASDAQ:PGEN), private equity firms are its largest shareholders with 43% ownershipKey Insights Significant control over Precigen by private equity firms implies that the general public has more power... |